Factors influencing post-transfusional platelet increment in pediatric patients given hematopoietic stem cell transplantation.
Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) always require platelet transfusions, but the increase in platelet count is often less than expected. Since factors responsible for poor response to platelet transfusions in this clinical setting are largely unknown, we performed a prospective study in 87 consecutive children transplanted in a single institution. The mean 16-h corrected count increment (CCI) of 598 platelet transfusions was 5.76 +/- 8.32 x 10(9)/l. Both before and after HSCT, 13.8% of patients had antibodies against HLA and/or platelet-specific antigens. Univariate analysis identified 12 factors significantly associated with a lower post-transfusion CCI, but only four reached statistical significance in the multivariate analysis. These four factors were concomitant therapy with vancomycin, alloimmunization, use of an Autopheresis cell separator for preparation of platelet concentrates and cytomegalovirus infection. We, therefore, suggest that a better response to platelet transfusions could be obtained by choosing a suitable cell separator, by avoiding the use of vancomycin and by adopting measures that reduce alloimmunization and CMV infection. Moreover, screening patients for HLA and platelet-specific antibodies before HSCT would identify the majority of subjects who will develop alloimmune refractoriness after transplantation and would allow the search for a compatible donor in advance.
Balduini
C L
CL
Department of Internal Medicine, IRCCS San Matteo-University of Pavia, Italy.
Salvaneschi
L
L
Klersy
C
C
Noris
P
P
Mazzucco
M
M
Rizzuto
F
F
Giorgiani
G
G
Perotti
C
C
Stroppa
P
P
Pumpo
M D
MD
Nobili
B
B
Locatelli
F
F
D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D016824:Antigens, Human Platelet / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D000075202:Contraindications; D016238:Cytapheresis / Q000295:instrumentation; D003586:Cytomegalovirus Infections / Q000097:blood / Q000150:complications; D005260:Female; D006680:HLA Antigens / Q000276:immunology; D006402:Hematologic Diseases / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D007518:Isoantibodies / Q000097:blood; D008297:Male; D010976:Platelet Count; D017713:Platelet Transfusion / Q000592:standards*; D011446:Prospective Studies; D014181:Transplantation Immunology; D014184:Transplantation, Homologous / Q000276:immunology; D014640:Vancomycin / Q000009:adverse effects / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D016824:Antigens, Human Platelet; D006680:HLA Antigens; D007518:Isoantibodies; D014640:Vancomycin